Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

Explore the recent expansion of new data new indications and new immunotherapies in the treatment of NSCLC with this comprehensive educational program featuring an on-demand webcast and downloadable slides from a live CCO webinar as well as an FAQ podcast and expert-authored commentary highlighting new data from WCLC Virtual 2021.

Share

Program Content

Activities

IO in Advanced/Metastatic NSCLC
The Evolving Role of Immunotherapy in Advanced NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 17, 2021

Expires: September 16, 2022

IO for Nonmetastatic NSCLC
Immunotherapy in Nonmetastatic NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 17, 2021

Expires: September 16, 2022

<i>EP</i>: Evolving IO for NSCLC
ExpressPoints
Understanding the Evolving Immuno-Oncology Treatment Paradigm in NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2021

Expires: September 22, 2022

Activities

FAQ: NSCLC Immunotherapy
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: November 23, 2021

Expires: November 22, 2022

<i>Podcast Pearls</i>: NSCLC IO FAQ
Podcast Pearls
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
PDF
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2021

Expires: November 30, 2022

Activities

WCLC 2021: IO Focus
New Findings in Lung Cancer From WCLC 2021: A Focus on Immunotherapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 05, 2021

Expires: October 04, 2022

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

Helsinn Healthcare SA

Merck Sharp & Dohme Corp.